Tin tức & Cập nhật
Xem bài viết Gan
Xem

HCV reinfection highest among people with ongoing injecting drug use
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.

RATIONALE-208 subanalyses boost tislelizumab potential for HCC
The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.

Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
In patients with chronic hepatitis B (CHB), treatment with the small interfering RNA JNJ-3989, in combination with a nucleos(t)ide analogue (NA), safely reduces levels of the hepatitis B surface antigen (HBsAg) for up to almost a year after the last dose, a new study has found.





